

December 5, 1974

Mr. F. F. Roasch

CTFA Subcommittee Meeting on Asbestos
in Talc

The meeting was held at Bristol-Myers, Hillside on December 4, 1974.
Those in attendance included:

Dr. Joseph Simko	(Colgate)
Mr. Harold Stanley	(Pfizer)
Mr. George Sandland	(Bristol-Myers, Chairman)
Mr. George Cohen	(Bristol-Myers)
Mr. Allan Harvey	(Vanderbilt)
Dr. Robert Rolfe	(J&J)
Dr. George Lee	(J&J)
Dr. John Travers	(Avon)

J&J pushed for the committee to submit the attached methods for consideration by the FDA. This was opposed by most members (Avon and Vanderbilt remained neutral) on the grounds that the work had been performed by only Avon and J&J. Reportedly, Mennen and Chasebrough-Ponds have DTA equipment but they have not started to examine the samples. Colgate and Pfizer have DTA equipment ordered but as yet do not even know the date of delivery.

I told the group of our DTA work at Debell and Richardson where we had 3 samples examined. For our information these were identified as: A. #4660 Talc; B. #4665 Talc; C. #4669 Talc. Debell and Richardson had reported sample "A" (#4660) to contain chrysotile because it had a peak at 850 degrees C. Dr. Rolfe felt that this was not proof of the presence of chrysotile because there must be two peaks (another at 680 degrees C).

We have agreed to submit another three blind samples to Debell & Richardson for additional DTA work. We will receive these from Rolfe (J&J).

It was reported by J&J and also by Avon that the FDA has never identified chrysotile in any U. S. cosmetic talc.

continued.....

PLAINTIFF'S
EXHIBIT
WCD-386

December 5, 1974

Mr. F. F. Roesch
CTFA Subcommittee Meeting on Asbestos
in Talc

Pfizer feels that DTA is being pushed by J&J because the FDA has similar equipment but they do not have an electron microscope. I feel that Pfizer is correct in this attitude but two different types of personnel are involved. It takes much greater skill to operate the electron microscope than it does to operate the DTA.

Reportedly, the FDA has commissioned the Franklin Institute, Philadelphia to start a research study of asbestos and talc.

The next meeting, to be held at Bristol-Myers, has been tentatively set for Tuesday February 4, 1975. In the meantime, Mr. Sandland will try to set up an informational type meeting with Norman Estrin (CTFA).

Roy R. Krammes

RRK/mw